These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 29772274)
1. Pharmacodynamic and pharmacokinetic characteristics of YMR-65, a tubulin inhibitor, in tumor-bearing mice. Fan A; Wei J; Yang M; Zhang Q; Zhang Y; Liu Q; Li N; Zhao D; Lu Y; Li J; Zhao J; Deng S; Zhang B; Zhu H; Chen X Eur J Pharm Sci; 2018 Aug; 121():74-84. PubMed ID: 29772274 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the pharmacokinetics, tissue distribution and excretion studies of YMR-65, a tubulin polymerization inhibitor with potential anticancer activity, in rats using UPLC-MS/MS. Fan A; Zhang Y; Zhang Q; Wei J; Lu X; Ren G; Zhao D; Li N; Zhu H; Chen X Xenobiotica; 2018 Sep; 48(9):920-926. PubMed ID: 29050520 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site. Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162 [TBL] [Abstract][Full Text] [Related]
4. Novel nicotinoyl pyrazoline derivates bearing N-methyl indole moiety as antitumor agents: Design, synthesis and evaluation. Chen K; Zhang YL; Fan J; Ma X; Qin YJ; Zhu HL Eur J Med Chem; 2018 Aug; 156():722-737. PubMed ID: 30041136 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and Biological Evaluation of 1-Methyl-1H-indole-Pyrazoline Hybrids as Potential Tubulin Polymerization Inhibitors. Zhang YL; Qin YJ; Tang DJ; Yang MR; Li BY; Wang YT; Cai HY; Wang BZ; Zhu HL ChemMedChem; 2016 Jul; 11(13):1446-58. PubMed ID: 27159418 [TBL] [Abstract][Full Text] [Related]
6. Synthesis, molecular properties prediction and biological evaluation of indole-vinyl sulfone derivatives as novel tubulin polymerization inhibitors targeting the colchicine binding site. Li W; Sun H; Xu F; Shuai W; Liu J; Xu S; Yao H; Ma C; Zhu Z; Xu J Bioorg Chem; 2019 Apr; 85():49-59. PubMed ID: 30599412 [TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, and Biological Evaluation of 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazole Analogues as Potential Anticancer Agents Targeting Tubulin Colchicine Binding Site. Liu YN; Wang JJ; Ji YT; Zhao GD; Tang LQ; Zhang CM; Guo XL; Liu ZP J Med Chem; 2016 Jun; 59(11):5341-55. PubMed ID: 27172319 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, pharmacodynamics and metabolism of a novel anticancer agent for prostate cancer. Yang J; Ahn S; Wu Z; Hwang DJ; Miller DD; Dalton JT Int J Oncol; 2012 Jul; 41(1):337-44. PubMed ID: 22576690 [TBL] [Abstract][Full Text] [Related]
9. Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer. Li CM; Lu Y; Chen J; Costello TA; Narayanan R; Dalton MN; Snyder LM; Ahn S; Li W; Miller DD; Dalton JT Pharm Res; 2012 Nov; 29(11):3053-63. PubMed ID: 22760659 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of 1, 4-dihydro indeno[1,2-c] pyrazole linked oxindole analogues as potential anticancer agents targeting tubulin and inducing p53 dependent apoptosis. Khan I; Garikapati KR; Shaik AB; Makani VKK; Rahim A; Shareef MA; Reddy VG; Pal-Bhadra M; Kamal A; Kumar CG Eur J Med Chem; 2018 Jan; 144():104-115. PubMed ID: 29268127 [TBL] [Abstract][Full Text] [Related]
11. A class of novel tubulin polymerization inhibitors exert effective anti-tumor activity via mitotic catastrophe. Zhang YL; Li BY; Yang R; Xia LY; Fan AL; Chu YC; Wang LJ; Wang ZC; Jiang AQ; Zhu HL Eur J Med Chem; 2019 Feb; 163():896-910. PubMed ID: 30580241 [TBL] [Abstract][Full Text] [Related]
12. Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties. Wu JD; Cui YJ; Zhou YG; Tang LQ; Zhang CM; Liu ZP Invest New Drugs; 2020 Feb; 38(1):29-38. PubMed ID: 30887253 [TBL] [Abstract][Full Text] [Related]
13. Synthesis of New N Elmeligie S; Khalil NA; Ahmed EM; Emam SH; Zaitone SA Biol Pharm Bull; 2016; 39(10):1611-1622. PubMed ID: 27725438 [TBL] [Abstract][Full Text] [Related]
14. Discovery of Novel Quinoline-Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity. Li W; Xu F; Shuai W; Sun H; Yao H; Ma C; Xu S; Yao H; Zhu Z; Yang DH; Chen ZS; Xu J J Med Chem; 2019 Jan; 62(2):993-1013. PubMed ID: 30525584 [TBL] [Abstract][Full Text] [Related]
15. Systemic delivery of nanoparticle formulation of novel tubulin inhibitor for treating metastatic melanoma. Mundra V; Peng Y; Kumar V; Li W; Miller DD; Mahato RI Drug Deliv Transl Res; 2015 Jun; 5(3):199-208. PubMed ID: 25924699 [TBL] [Abstract][Full Text] [Related]
16. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer. Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of (1-aryl-1H-pyrazol-4-yl) (3,4,5-trimethoxyphenyl)methanone derivatives as tubulin inhibitors. Zhai M; Wang L; Liu S; Wang L; Yan P; Wang J; Zhang J; Guo H; Guan Q; Bao K; Wu Y; Zhang W Eur J Med Chem; 2018 Aug; 156():137-147. PubMed ID: 30006160 [TBL] [Abstract][Full Text] [Related]
18. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway. Mao J; Wang D; Wang Z; Tian W; Li X; Duan J; Wang Y; Yang H; You L; Cheng Y; Bian J; Chen Z; Yang Y Cancer Lett; 2016 Sep; 380(1):134-43. PubMed ID: 27349166 [TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of pyrazole-oxindole conjugates targeting tubulin polymerization as new anticancer agents. Kamal A; Shaik AB; Jain N; Kishor C; Nagabhushana A; Supriya B; Bharath Kumar G; Chourasiya SS; Suresh Y; Mishra RK; Addlagatta A Eur J Med Chem; 2015 Mar; 92():501-13. PubMed ID: 25599948 [TBL] [Abstract][Full Text] [Related]
20. A potent anticancer agent of shikonin derivative targeting tubulin. Baloch SK; Ma L; Xu GH; Bai LF; Zhao H; Tang CY; Pang YJ; Yang RW; Wang XM; Lu GH; Yang YH Chirality; 2015 Mar; 27(3):274-80. PubMed ID: 25663187 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]